Revance Therapeutics Inc (RVNC)

[marthambles]

So, just to close the loop, the problem, if there is one, is that those analyses showing continuing efficacy for 50% of the population at 6 months were not included in the label. Question is whether this prevents Revance from promoting its product based upon the unincluded analyses.